Targeting Bcl-2 alone with agents such as ABT-199 has yielded limited clinical benefit in MM; except for in patients that carry the t(11;14)(q13;32)] chromosomal abnormality and whose tumor cells are more dependent on Bcl-2 compared to Mcl-1 or Bcl-xL [35]. Here, BCL2L1 is linked to Miyoshi myopathy.